fbpx

Dipyridamole

CLASS

  • anti-platelet + vasodilator

MECHANISM OF ACTION

  • potentiates the effect of prostacyclin or by inhibiting phosphodiesterase enzyme activity -> increase intracellular cAMP
  • inhibits cellular uptake of adenosine -> more available to act on coronary vessels -> vasodilation

PHARMACEUTICS

  • yellow crystalline powder
  • bitter taste
  • oral tablet
  • immediate and slow release

DOSE

  • 150mg SR BD
  • 1-2mg/kg QID

INDICATIONS

  1. anti-anginal
  2. anti-thrombotic for prostatic valves
  3. anti- thrombotic in ischaemic TIA’s/CVA
  4. PVD
  5. pulmonary hypertension

ADVERSE EFFECTS

  • hypotension
  • drug interactions: can increased plasma levels of adenosine, antagonism of cholinesterase inhibitors

PHARMACOKINETICS

  • Absorption – bioavailability = 50%
  • Distribution – t1/2 alpha = 40min
  • Metabolism – hepatic
  • Elimination – bile, t1/2 beta = 10hrs

CCC Pharmacology Series

Critical Care

Compendium

Chris is an Intensivist and ECMO specialist at The Alfred ICU, where he is Deputy Director (Education). He is a Clinical Adjunct Associate Professor at Monash University, the Lead for the  Clinician Educator Incubator programme, and a CICM First Part Examiner.

He is an internationally recognised Clinician Educator with a passion for helping clinicians learn and for improving the clinical performance of individuals and collectives. He was one of the founders of the FOAM movement (Free Open-Access Medical education) has been recognised for his contributions to education with awards from ANZICS, ANZAHPE, and ACEM.

His one great achievement is being the father of three amazing children.

On Bluesky, he is @precordialthump.bsky.social and on the site that Elon has screwed up, he is @precordialthump.

| INTENSIVE | RAGE | Resuscitology | SMACC

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.